TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05159700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.
Study: NCT05745597

Intervention type: OTHER
Intervention: Follow up
Description: Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
Study: NCT06414356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
Study: NCT05667441

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Risk profiling
Description: Personalized risk profiling for lifestyle and genetics.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Risk profiling
Description: Personalized risk profiling for lifestyle and genetics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: Coaching
Study: NCT06414356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Magnesium sulfate
Description: Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
Study: NCT04642404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex 100 mg/mL Oral Solution
Description: Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex 100 mg/mL Oral Solution
Description: Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug will be a solution with the same taste, texture and color as the drug.
Study: NCT04637555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
Study: NCT05489666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nature Made Vitamin D3 5,000 IU, 125mcg
Description: Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
Study: NCT02814747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quantitive study: 500 patients likely to be candidates for HTS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qualitative study: 30 patients who have benefited from HTS
Study: NCT05459519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dengzhanxixin Capsule plus Placebo Capsule
Description: Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 4 capsules each time, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dengzhanxixin Capsule plus Placebo Capsule
Description: Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
Study: NCT04882930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Near-Infrared Spectroscopy (fNIRS)
Description: All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Study: NCT06282965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin (1-7)
Description: The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin (1-7)
Description: The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Sterile solution of 0.9% NaCl in water.
Study: NCT05482659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education on healthy nutrition and regular physical activity based on the transtheoretic model
Description: An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
Study: NCT05656833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional 1927nm Low-Powered Diode Laser
Description: Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Cysteamine
Description: Topical Cysteamine cream will be used on the entire face.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Cysteamine
Description: Topical Cysteamine cream will be used on the entire face.
Study: NCT05050396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis
Description: Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis
Description: Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
Study: NCT05063851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride Tablets
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Study: NCT06357468

Intervention type: OTHER
Intervention: midwife-led births in low risk women in pregnancy
Description: Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
Study: NCT05393739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation (TBS) procedure
Description: The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation (TBS) procedure
Description: The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta burst transcranial magnetic stimulation (TBS) procedure
Description: The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
Study: NCT05410262

Intervention type: OTHER
Intervention: Evaluation of CT images
Description: A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
Study: NCT05045170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influence of propofol sedation on memory consolidation and 'working memory'
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influence of dexmedetomidine sedation on memory consolidation and 'working memory'
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Influence of spinal anesthesia on memory consolidation and 'working memory'
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study: NCT05893433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside cycling
Description: participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
Study: NCT06390787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Vitamin B6
Description: We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6
Description: We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: We gave only Zofran as a treatment for managing nausea and vomiting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: We gave only Metoclopramide as a treatment for managing nausea and vomiting.
Study: NCT04912895

Intervention type: DEVICE
Group type: OTHER
Intervention: PneumoniaCheck
Description: Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PneumoniaCheck
Description: Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PneumoniaCheck
Description: Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
Study: NCT06376110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Antioxidant Serum
Description: An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Antioxidant Serum
Description: An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AviClear Laser
Description: The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AviClear Laser
Description: The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
Study: NCT05568147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin tablet
Description: When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: When patients are randomized into the placebo group, they will receive placebo orally once a day.
Study: NCT06344754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified education
Description: Training will be provided with gamification method. Data will be collected with \&#34;Introductory Information Form\&#34; and \&#34;Family Planning Attitude Scale\&#34;. The family planning attitude scale will be administered as both pre and post test.
Study: NCT05757531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3437943
Description: Administered SC.
Study: NCT04889339

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test brace versus control brace: Immediate correction
Description: The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
Study: NCT05586698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.